ALDURAZYM [Packungsbeilage].Novato, CA: BioMarin Pharmaceutical Inc; 2013.

All about the Human Genome Project. Website des National Human Genome Research Institute.
Aktualisierung 01.10.2015. Zugriff 11.09.2018.

ASH Clinical News. Researchers report first successful gene therapy for hemophilia A. Website der American Society of Hematology. .Zugriff 11.09.2018.

Brineura [Packungsbeilage]. Novato, CA: BioMarin Pharmaceutical Inc; 2018.

Current trends update: acquired immunodeficiency syndrome (AIDS) among patients with hemophilia—United States. Website der Centers for Disease Control. Zugriff 11.09.2018.

Franklin RE, Gosling RG. Molecular configuration in sodium thymonucleate. Nature. 1953;171(4356):740-741.

Gene therapy—a revolution in progress: human genetics and medical research. Website der National Institutes of Health. Zugriff 11.09.2018

Genetic timeline. Website des National Human Genome Research Institute. Zugriff 11.09.2018.

Giangrande P. The future of hemophilia treatment: longer-acting factor concentrates versus gene therapy. Semin Thromb Hemost. 2016;42(5):513-517.

Gregor Mendel: the father of modern genetics. Website des Office of NIH History. Zugriff 11.09.2018.

Hemophilia: from plasma to recombinant factors. Website der American Society of Hematology. Zugriff 11.09.2018.

Highlights of transfusion medicine history. Website der AABB. Zugriff 11.09.2018.

History. Website von BioMarin. Zugriff 11.09.2018.

History of bleeding disorders. Website der National Hemophilia Foundation. Zugriff 11.09.2018.

Hoffman M. FVIIa: you’ve come a long way, baby! Blood. 2008;112(8):3002-3003.

KUVAN [Packungsbeilage]. Novato, CA: BioMarin Pharmaceutical Inc; 2016.

Manno CS, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342-347.

Morfini M, Coppola A, Franchini M, Di Minno G. Clinical use of factor VIII and factor IX concentrates. Blood Transfus. 2013;11(suppl 4):s55-s63.

NAGLAZYM [Packungsbeilage]. Novato, CA: BioMarin Pharmaceutical Inc; 2013.

Ng HJ, Lee LH. Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients. Vasc Health Risk Manag. 2006;2(4):433-440.

Powell JS. Longer-acting clotting factor concentrates for hemophilia. J Thromb Haemost. 2015;13(suppl 1):S167-S175.

Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-e47.

Tratschin J-D, West MH, Sandbank T, Carter BJ. A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol. 1984;4(10):2072-2081.

VIMIZIM [Packungsbeilage]. Novato, CA: BioMarin Pharmaceutical Inc; 2014.

Watson JD, Crick FH. Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature. 1953;171(4356):737-738.

Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature. 1984;312(5992):330-337.